
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is demonstrating strong progress across its various programs, as evidenced by numerous upcoming milestones and catalysts, commendable preliminary data from its NBTXR3 and Nanoray platforms in multiple indications, and continued enrollment in its ISTs. With a sizable TAM estimated at $12-14B in just its three initial indications of focus, the company has significant potential for growth and upside. Additionally, its strong partnership with JNJ and positive updates from its lead program NBTXR3 give confidence in its future success.
Bears say
Nanobiotix is heavily reliant on the success of its nanotechnology-based product candidate, NBTXR3, which is still in clinical trials and faces potential risks and delays. Additionally, the company's valuation is heavily based on its potential success in the treatment of cancer, which is a highly competitive and complex market. The recent operational progress and ongoing partnerships do provide some upside potential, but overall, the success of the company's product candidate remains uncertain.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares